Irinotecan–temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial-Reference-Cited by-同舟云学术

Irinotecan–temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial

Published:2017-07 Issue:7 Volume:18 Page:946-957
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Mody Rajen,Naranjo Arlene,Van Ryn Collin,Yu Alice L,London Wendy B,Shulkin Barry L,Parisi Marguerite T,Servaes Sabah-E-Noor,Diccianni Mitchell B,Sondel Paul M,Bender Julia G,Maris John M,Park Julie R,Bagatell Rochelle

Funder

National Institutes of Health and NCI grants

Publisher

Elsevier BV

Subject

Oncology

Reference62 articles.

1. Advances in risk classification and treatment strategies for neuroblastoma;Pinto;J Clin Oncol,2015

2. Phase II study of irinotecan and temozolomide in children with relapsed or refractory neuroblastoma: a Children's Oncology Group study;Bagatell;J Clin Oncol,2011

3. Irinotecan plus temozolomide for relapsed or refractory neuroblastoma;Kushner;J Clin Oncol,2006

4. Targeting PI3K/Akt/mTOR signaling in cancer;Porta;Front Oncol,2014

5. Inhibitors of mammalian target of rapamycin downregulate MYCN protein expression and inhibit neuroblastoma growth in vitro and in vivo;Johnsen;Oncogene,2008

Cited by 220 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comprehensive understanding of the adverse effects associated with temozolomide: a disproportionate analysis based on the FAERS database;Frontiers in Pharmacology;2024-08-23

2. CAR T-cell-mediated delivery of bispecific innate immune cell engagers for neuroblastoma;Nature Communications;2024-08-21

3. Paediatric strategy forum for medicinal product development of PI3-K, mTOR, AKT and GSK3β inhibitors in children and adolescents with cancer;European Journal of Cancer;2024-08

4. Preclinical Pediatric Molecular Analysis for Therapy Choice (MATCH);2024-07-23

5. Neuroblastoma—A Review of Combination Immunotherapy;International Journal of Molecular Sciences;2024-07-15